Form 10-K HERON THERAPEUTICS, INC. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Heron Therapeutics (HRTX) PT Lowered to $20 at Cantor Fitzgerald
March 1, 2022 7:22 AM ESTCantor Fitzgerald analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $20.00 (from $26.00) while maintaining a Neutral rating.
... MoreHeron Therapeutics (HRTX) PT Lowered to $13 at Cowen
March 1, 2022 6:54 AM ESTCowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $13.00 (from $31.00) while maintaining an Outperform rating following disappointing Q4 results.
The analyst commented, "Heron reported disappointing 4Q21 earnings with Zynrelef reaching sales of only $0.8MM (-61% Q/Q). We... More
